Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Neurocrine Biosciences
Age
13–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Medically confirmed diagnosis of schizophrenia
Participant is receiving a stable regimen of background antipsychotic medication
Plasma levels for at least 1 of the participant's antipsychotic medications must be detectable by an available assay
Participant is an outpatient with stable symptomatology
Participant must have an adult informant (for example, a family member, relative, partner, social worker, caseworker, residential facility staff, or nurse)
You may not be if
Has a history of treatment resistant schizophrenia
Have a clinically significant unstable medical condition in the judgement of the investigator or any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit
Prior (within 6 months of Screening) or concomitant use of any vesicular monoamine transporter 2 (VMAT2) inhibitor (that is, valbenazine, reserpine, tetrabenazine, deutetrabenazine); or a history of intolerance to VMAT2 inhibitors
Clareo Health | Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
